Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism
Abstract
SARS-CoV-2 Omicron variants have generated a world-wide health crisis due to resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of antibodies induced by vaccination. Here, we describe the SARS-CoV-2 neutralizing SP1-77 antibody that was generated from a humanized mouse model with a single human VH1-2 and Vκ1-33-associated with immensely diverse complementarity-determining-region-3 (CDR3) sequences. SP1-77 potently and broadly neutralizes SARS-CoV-2 variants of concern and binds the SARS-CoV-2 spike protein receptor-binding-domain (RBD) via a novel-CDR3-based mode. SP1-77 does not block RBD-binding to the ACE2-receptor or endocytosis step of viral entry, but rather blocks membrane fusion. Our findings provide the first mechanistic insight into how a non-ACE2 blocking antibody potently neutralizes SARS-CoV-2, which may inform strategies for designing vaccines that robustly neutralize current and future SARS-CoV-2 variants.
Competing Interest Statement
M.T. and F.W.A. are authors on a patent application that describes the general type of mouse model used (US 16/973,125). S.L., B.F.H. and F.W.A. are authors on patent applications describing the antibodies reported (63/256,384 and 63/305,424).
Subject Area
- Biochemistry (11561)
- Bioengineering (8622)
- Bioinformatics (28861)
- Biophysics (14793)
- Cancer Biology (11918)
- Cell Biology (17159)
- Clinical Trials (138)
- Developmental Biology (9302)
- Ecology (14019)
- Epidemiology (2067)
- Evolutionary Biology (18128)
- Genetics (12144)
- Genomics (16615)
- Immunology (11706)
- Microbiology (27689)
- Molecular Biology (11384)
- Neuroscience (60089)
- Paleontology (447)
- Pathology (1847)
- Pharmacology and Toxicology (3183)
- Physiology (4878)
- Plant Biology (10276)
- Synthetic Biology (2849)
- Systems Biology (7289)
- Zoology (1618)